Cannabis Toxidrome: Marijuana or Weed

Introduction: Cannabis, derived from the plant Cannabis sativa, is one of the most commonly used psychoactive substances worldwide. With increasing legalization and availability, clinicians are seeing more cases of cannabis intoxication, both from traditional marijuana and synthetic cannabinoids. This article delves into the detailed pathophysiology, clinical presentation, differential diagnosis, and management of cannabis toxidrome, offering insights for Clinicians.

Pathophysiology of Cannabis Intoxication

Cannabis contains over 100 cannabinoids, of which Δ9-tetrahydrocannabinol (THC) is the primary psychoactive compound. THC exerts its effects primarily through the endocannabinoid system, binding to CB1 and CB2 receptors:

• CB1 receptors: Predominantly found in the central nervous system (CNS), these receptors are responsible for most of the psychoactive and neurological effects, including euphoria, altered cognition, and motor impairment.
• CB2 receptors: Located primarily in immune cells and peripheral tissues, these receptors are involved in modulating immune responses.

The activation of CB1 receptors leads to alterations in neurotransmitter release, including dopamine, gamma-aminobutyric acid (GABA), and glutamate. The interplay between these neurotransmitters explains the diverse CNS effects of cannabis intoxication, ranging from relaxation and euphoria to anxiety, panic, and psychosis.

Clinical Features of Cannabis Toxidrome

Cannabis intoxication presents with a wide array of symptoms depending on the dose, route of administration, patient tolerance, and co-ingestion of other substances (e.g., alcohol or synthetic cannabinoids). The clinical spectrum can be divided into mild, moderate, and severe intoxication.

1. Neurological and Psychiatric Manifestations

• Mild Intoxication:
  • Euphoria and relaxation
  • Altered perception of time and space
  • Heightened sensory experiences (colors, sounds, and tastes)
• Moderate Intoxication:
  • Cognitive dysfunction (memory impairment, poor concentration)
  • Psychomotor slowing
  • Dysphoria and paranoia, especially in inexperienced users or those consuming high doses
• Severe Intoxication:
  • Cannabis-induced psychosis: Hallucinations, paranoia, and delusions, particularly in susceptible individuals (those with a history of schizophrenia or bipolar disorder).
  • Cerebellar dysfunction: Ataxia, dysarthria, and uncoordinated movements, especially in acute overuse.

2. Cardiovascular Effects

• Tachycardia: This is the most common cardiovascular effect, occurring in up to 80% of patients. The mechanism is thought to involve increased sympathetic activity and suppression of parasympathetic outflow.
• Hypertension: Often transient, related to the tachycardia and increased sympathetic drive.
• Hypotension and syncope: Although rare, orthostatic hypotension can occur in some patients, particularly the elderly or those with co-ingestions. THC-induced vasodilation and impaired baroreceptor reflexes play a role here.
• Myocardial infarction (MI): Though uncommon, there are documented cases of cannabis use precipitating MI, particularly in individuals with underlying coronary artery disease. The proposed mechanisms include THC-induced catecholamine release, increased heart rate, and vasospasm.

3. Gastrointestinal Manifestations

• Cannabinoid Hyperemesis Syndrome (CHS):
  • Characterized by cyclical vomiting, nausea, and abdominal pain in chronic cannabis users.
  • Interestingly, patients with CHS often report compulsive hot water bathing, which temporarily alleviates symptoms by activating thermoregulatory pathways that counteract the effects of THC.
  • Pathophysiology: It is hypothesized that chronic overstimulation of CB1 receptors in the gastrointestinal tract leads to dysregulation of gastrointestinal motility and nausea control.

4. Respiratory Effects

• Smoking-related complications: Cannabis smoke contains many of the same toxins as tobacco smoke, increasing the risk for bronchitis, chronic obstructive pulmonary disease (COPD), and lung infections.
• Synthetic cannabinoids: These can cause more severe respiratory depression, especially in combination with other CNS depressants.

Differential Diagnosis of Cannabis Toxidrome

Given the wide array of presenting symptoms, cannabis toxidrome can mimic other conditions, especially in the emergency department. A detailed history, including substance use and route of administration, is crucial.

1. Other Toxidromes

• CNS Depressants (alcohol, benzodiazepines, opioids): These substances can cause overlapping features, such as ataxia, altered mental status, and respiratory depression.
• Anticholinergic toxicity: Patients may present with hallucinations, tachycardia, and dry mucous membranes.
• Sympathomimetic toxidrome (e.g., cocaine, amphetamines): Patients may present with agitation, tachycardia, and hypertension, but they usually have more pronounced hyperthermia and mydriasis.

2. Psychiatric Disorders

• Acute anxiety disorders or panic attacks: These may be indistinguishable from cannabis-induced anxiety or paranoia without a history of substance use.
• Primary psychotic disorders (schizophrenia, bipolar disorder): Cannabis-induced psychosis may resemble these, but a detailed drug use history can aid in differentiating the two.

3. Cardiovascular Disorders

• Myocardial infarction: Particularly in older patients with a history of coronary artery disease, cannabis use can exacerbate chest pain and should not be dismissed as purely anxiety-related.

Management of Cannabis Toxidrome

1. Supportive Care

• Calm environment: Most cases of cannabis intoxication, especially in acute settings, resolve with simple reassurance and a calm, quiet environment.
• Hydration: Intravenous fluids should be considered for patients with vomiting, hypotension, or dehydration.

2. Sedation for Agitation or Psychosis

• Benzodiazepines (e.g., lorazepam or diazepam) are the first-line agents for managing anxiety, agitation, or panic attacks induced by cannabis. They also help control severe psychosis or hallucinations.
• Antipsychotics (e.g., haloperidol or olanzapine) may be required in severe cases of cannabis-induced psychosis, especially in patients with a personal or family history of psychiatric illness.

3. Management of Cannabinoid Hyperemesis Syndrome

• Symptomatic treatment: Anti-emetics like ondansetron or metoclopramide may provide some relief, though the response is often inadequate in CHS.
• Hot showers: Patients often self-report relief from hot baths or showers, but this should be corroborated by clinical observation.
• Definitive treatment: The cessation of cannabis use is the only effective long-term management of CHS.

4. Cardiovascular Support

• Tachycardia: Often, no specific treatment is required for cannabis-induced tachycardia, but monitoring is essential, especially in patients with pre-existing heart conditions.
• Hypertension: Short-acting antihypertensives like labetalol or nitroglycerin can be considered if the patient is hypertensive and symptomatic.
• Chest pain: Consider obtaining an ECG and cardiac enzymes to rule out myocardial infarction, especially in patients at risk.

Prognosis and Long-term Considerations

For most patients, cannabis intoxication resolves without long-term sequelae. However, certain patient populations, such as those with a predisposition to psychiatric disorders or cardiovascular disease, may experience significant adverse effects. The recurrent use of synthetic cannabinoids, which are often more potent and unpredictable, can lead to more severe and sometimes fatal outcomes, including seizures, kidney injury, and multiorgan failure.

Conclusion

As cannabis use becomes more widespread, Clinicians need to be well-versed in the recognition and management of cannabis toxidrome. Most cases resolve with supportive care, but understanding the more severe manifestations, particularly those related to synthetic cannabinoids, cannabinoid hyperemesis syndrome, and cardiovascular complications, is vital for providing comprehensive care.

By adopting a systematic approach to diagnosis, ensuring appropriate supportive care, and managing complications, healthcare providers can effectively treat patients presenting with cannabis intoxication and its associated syndromes.